BCMA Targeted Therapies Market

BCMA Targeted Therapies, 2017-2030

  • Lowest Price Guaranteed From USD 2,499

  • Companies Covered
    114

  • Pages
    143

  • View Count
    9589

Chapter Outlines

Chapter 2  provides an executive summary of the insights captured in our research. It offers a high level view on the current state of the BCMA targeted therapies market and its likely evolution.

Chapter 3  provides a general introduction to BCMA, highlighting its expression profile, role in progression of multiple myeloma and mechanism of action. In this section, we have talked about the current research landscape of the human BCMA and its emergence for the treatment of multiple myeloma. Further, we have briefly discussed the molecules (bispecific antibodies, ADCs and CAR-T cells) that are being exploited for the development of BCMA-specific drug candidates.

Chapter 4  provides a comprehensive overview of the current landscape of the BCMA targeted therapies market. It includes information on the drug candidates that are currently in different stages of development (both clinical and preclinical / discovery). It presents a detailed analysis of the pipeline on the basis of current phase of development, type of molecules and key players involved in this space. We have also provided details on additional parameters (such as associated domains and transfection methods) being utilized for the development of T-cell based BCMA-specific therapies. In addition, the chapter includes an overview on the developer landscape based on the size and the activity of the industry / non-industry players and a geographical representation mapping the presence of various organizations involved in the clinical development of candidates in this field.

Chapter 5  presents detailed profiles of the BCMA targeted therapies in clinical phases of development (phase I/II and phase I). Each profile covers information on drug specifications, mechanism of action, dosage regimen, technology overview, manufacturing details, key preclinical / clinical findings and collaborations. In addition, we have also provided a comparative analysis on the design of clinical trials being conducted for several molecules, highlighting the study goals of the trials, primary and secondary endpoints being evaluated and the interim trial results.

Chapter 6  presents details on the investments and grants received by companies working on the development of BCMA targeted therapies. The analysis highlights the growing interest of the venture capital community and other strategic investors in this market.

Chapter 7  features an elaborate discussion on the collaborations and partnerships that have been inked amongst players in this market. We have also discussed the various partnership models that have been implemented, highlighting the most common forms of deals / agreements prevalent in this domain.

Chapter 8  provides a comprehensive market forecast, highlighting the future potential of the market till 2030. It includes future sales projections of the molecules in clinical stages of development (phase I/II and phase I). The sales potential and growth opportunity is based on the target patient populations, existing / likely future competition, likely adoption rates, the type of molecule and likely price points.

Chapter 9  summarizes the overall report and provides a recap of the key takeaways from the study. It also presents our independent opinion on the future of BCMA targeted therapies market based on the research and analysis described in previous chapters.

Chapter 10  is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 11  is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE
1.1. Chapter Overview
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Chapter Overview
3.2. The B-Cell Maturation Antigen
3.2.1. Overview
3.2.2. Mechanism of Action
 
3.3. Drug Classes for BCMA Targeted Therapies
3.3.1. Bispecific Antibodies
3.3.2. Antibody Drug Conjugates
3.3.3. Chimeric Antigen Receptor T-Cells
 
3.4. BCMA Targeted Therapies and Research Landscape
3.5. Emergence of BCMA as a Therapeutic Target for the Treatment of Multiple Myeloma
3.5.1. Multiple Myeloma: Introduction and Epidemiology
3.5.2. Multiple Myeloma: Current Treatment Landscape
3.5.3. Multiple Myeloma: Emergence of Novel Targets
3.5.3.1. Immunotherapeutic Targets
3.5.3.2. BCMA: A Promising Antigen
 
3.6. BCMA Related Targets: A Case Study
 
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. BCMA Targeted Therapies: Development Pipeline
4.3. BCMA Targeted Therapies: Distribution by Phase of Development
4.4. BCMA Targeted Therapies: Distribution by Type of Molecule
4.5. BCMA Targeted Therapies: Distribution by Type of Developer
4.6. BCMA Targeted Therapies: Distribution by Indication
4.7. BCMA Targeted Therapies: Geographical Landscape
4.8. BCMA Targeted Therapies: Developer Landscape
 
5. DRUG PROFILES: CLINICAL MOLECULES
5.1. Chapter Overview
 
5.2. bb2121 (bluebird bio, Celgene)
5.2.1. Drug Specifications
5.2.2. Trial Design and Dosage Regimen
5.2.3. Manufacturing Information
5.2.4. Key Preclinical / Clinical Findings
5.2.5. Collaborations
 
5.3. CART-BCMA (Novartis, Abramson Cancer Center of the University of Pennsylvania)
5.3.1. Drug Specifications
5.3.2. Trial Design and Dosage Regimen
5.3.3. Manufacturing Information
5.3.4. Key Preclinical / Clinical Findings
5.3.5. Collaborations
 
5.4. Anti-BCMA CAR-T (National Cancer Institute)
5.4.1. Drug Specifications
5.4.2. Trial Design and Dosage Regimen
5.4.3. Key Preclinical / Clinical Findings
 
5.5. Anti-BCMA CAR-T (Southwest Hospital, China)
5.5.1. Drug Specifications
5.5.2. Trial Design and Dosage Regimen
 
5.6. GSK2857916 / J6M0-mcMMAF (GSK, Seattle Genetics)
5.6.1. Drug Specifications
5.6.2. Mechanism of Action
5.6.3. Trial Design and Dosage Regimen
5.6.4. Key Preclinical / Clinical Findings
5.6.5. Collaborations
 
5.7. AMG 420 / BI 836909 (Amgen, Boehringer Ingelheim)
5.7.1. Drug Specifications
5.7.2. Mechanism of Action
5.7.3. Trial Design and Dosage Regimen
5.7.4. Technology Overview
5.7.5. Key Preclinical / Clinical Findings
5.7.6. Collaborations
 
5.8. BCMA Targeted Therapies: Clinical Development Analysis
5.8.1. Clinical Development Analysis: Study Goal Comparison
5.8.2. Clinical Development Analysis: Clinical Endpoint Comparison
5.8.3. Clinical Development Analysis: Interim Trial Results Comparison
 
6. VENTURE CAPITAL INTEREST
6.1. Chapter Overview
6.2. BCMA Targeted Therapies: List of Funding Instances
6.3. Funding Instances: Distribution by Year
6.4. Funding Instances: Distribution by Type of Model
6.5. Leading Players: Distribution by Number of Funding Instances
6.6. Most Active Venture Capital Firms / Investors
 
7. RECENT COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models / Agreements
7.3. BCMA Targeted Therapies: Recent Collaborations
7.4. Recent Collaborations: Distribution by Year
7.5. Recent Collaborations: Distribution by Type of Model
7.6. Recent Collaborations: Distribution by Type of Molecule
7.7. Recent Collaborations: Most Active Companies
 
8. MARKET FORECAST
8.1. Chapter Overview
8.2. Scope and Limitation
8.3. Forecast Methodology
8.4. Overall BCMA Targeted Therapeutics Market
8.5. BCMA Targeted Therapeutics Market: Drug Specific Forecasts
 
8.5.1. bb2121 (bluebird bio, Celgene)
8.5.1.1. Target Patient Population
8.5.1.2. Sales Forecast
 
8.5.2. CART-BCMA (Novartis, Abramson Cancer Center of the University of Pennsylvania)
8.5.2.1. Target Patient Population
8.5.2.2. Sales Forecast
 
8.5.3. Anti-BCMA CAR-T (National Cancer Institute)
8.5.3.1. Target Patient Population
8.5.3.2. Sales Forecast
 
8.5.4. Anti-BCMA CAR-T (Southwest Hospital, China)
8.5.4.1. Target Patient Population
8.5.4.2. Sales Forecast
 
8.5.5. GSK2857916 / J6M0-mcMMAF (GSK, Seattle Genetics)
8.5.5.1. Target Patient Population
8.5.5.2. Sales Forecast
 
8.5.6. AMG 420 / BI836909 (Amgen, Boehringer Ingelheim)
8.5.6.1. Target Patient Population
8.5.6.2. Sales Forecast
 
9. CONCLUSION
9.1. BCMA has Emerged as a Potential Antigen for the Treatment of Multiple Myeloma
9.2. Led by a Number of Technological Advances, CAR- T Therapies are the Current Flag-Bearer
9.3. Even Though Big Pharmaceutical Companies Dominate the Current Space, Several Start-Ups / Small Companies Have Emerged
9.4. Growing Partnerships and Venture Capital Support are Indicative of the Future Potential
9.5. Once Approved, BCMA Targeted Therapies are Poised to Achieve an Accelerated Growth
 
10. APPENDIX 1: TABULATED DATA
 
11. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1  BCMA Receptor and Ligand Family
Figure 3.2  Components of an Antibody
Figure 3.3  Components of ADCs
Figure 3.4  CAR-T: Structure and Domains
Figure 3.5  Publication Trend: Distribution by Year (2004-2017)
Figure 3.6  Multiple Myeloma: Global Epidemiological Distribution
Figure 3.7  Advantages of BCMA as a Therapeutic Target
Figure 4.1  BCMA Targeted Therapies: Distribution by Phase of Development
Figure 4.2  BCMA Targeted Therapies: Distribution by Type of Molecule
Figure 4.3  BCMA Targeted Therapies: Distribution by Type of Molecule and Phase of Development
Figure 4.4  BCMA Targeted Therapies: Distribution by Type of Developer
Figure 4.5  BCMA Targeted Therapies: Distribution by Indication
Figure 4.6  Developers of BCMA Targeted Therapies: Geographical Presence
Figure 4.7  BCMA Targeted Therapies: Distribution by Developer and Molecule Type
Figure 6.1  Funding Instances: Number of Instances, Pre-2007-2017
Figure 6.2  Funding Instances: Amount Invested, Pre-2007-2017 (USD Million)
Figure 6.3  Funding Instances: Distribution by Type of Funding, 2001-2017
Figure 6.4  Funding Instances: Distribution by Total Amount Invested, 2001-2017 (USD Million)
Figure 6.5  Funding Instances: Distribution by Range of Amount Invested by Type of Funding (USD Million)
Figure 6.6  Most Active Players: Distribution by Number of Funding Instances, 2001-2017
Figure 6.7  Most Active Venture Capital Firms / Investors: Distribution by Number of Funding Instances, 2001-2017
Figure 7.1  BCMA Targeted Therapies Collaboration Landscape: Distribution by Collaborators, Type and Year of Collaboration
Figure 7.2  Recent Collaborations: Distribution by Year
Figure 7.3  Recent Collaborations: Distribution by Type of Model
Figure 7.4  Recent Collaborations: Distribution by Type of Molecule
Figure 7.5  Recent Collaborations: Distribution by Type of Molecule and Partnership Model
Figure 7.6  Recent Collaborations: Most Active Players
Figure 8.1  Overall BCMA Targeted Therapies Market (USD Million), Through 2030, Base Scenario
Figure 8.2  BCMA Targeted Therapies Market: Distribution by Type of Molecule, 2030 (USD Million)
Figure 8.3  BCMA Targeted Therapies Market: Distribution of Market Share, 2030 (USD Million)
Figure 8.4  bb2121 Sales Forecast (USD Million), Through 2030, Base Scenario
Figure 8.5  CART-BCMA Sales Forecast (USD Million), Through 2030, Base Scenario
Figure 8.6  Anti-BCMA CAR-T Sales Forecast (USD Million), Through 2030, Base Scenario
Figure 8.7  Anti-BCMA CAR-T Sales Forecast (USD Million), Through 2030, Base  Scenario
Figure 8.8  GSK2857916 / J6M0-mcMMAF Sales Forecast (USD Million), Through 2030, Base Scenario
Figure 8.9  AMG 420 / BI 836909 Sales Forecast (USD Million), Through 2030, Base Scenario
Figure 9.1  Overall BCMA Targeted Therapies Market Summary (USD Million): 2024, 2027, 2030

List of Tables

Table 3.1  Key Characteristics of CAR-T Cells
Table 3.2  Marketed Therapeutics for Multiple Myeloma
Table 3.3  Immunotherapeutic Targets for the Treatment of Multiple Myeloma
Table 4.1  BCMA Targeted Therapies: Development Pipeline
Table 4.2  T-Cell Based BCMA Targeted Therapies: Transfection Methods and Associated Domains
Table 5.1  BCMA Targeted Therapies: List of Drugs Profiled
Table 5.2  Clinical Development Analysis: Study Goal Comparison
Table 5.3  Clinical Development Analysis: Clinical Endpoint Comparison
Table 5.4  Clinical Development Analysis: Interim Trial Result Comparison
Table 6.1  List of Funding Instances and Investors, 2001-2017
Table 6.2  Types of Funding Instances, 2001-2017
Table 7.1  BCMA Targeted Therapies: Recent Collaborations (2009-2017)
Table 8.1  BCMA Targeted Therapies: Estimated Launch Years
Table 8.2  bb2121: Target Patient Population
Table 8.3  CART-BCMA: Target Patient Population
Table 8.4  Anti-BCMA CAR-T: Target Patient Population
Table 8.5  Anti-BCMA CAR-T: Target Patient Population
Table 8.6  GSK2857916 / J6M0-mcMMAF: Target Patient Population
Table 8.7  AMG 420 / BI836909: Target Patient Population
Table 10.1  Publication Trend: Distribution by Year (2004-2017)
Table 10.2  BCMA Targeted Therapies: Distribution by Phase of Development
Table 10.3  BCMA Targeted Therapies: Distribution by Type of Molecule
Table 10.4  BCMA Targeted Therapies: Distribution by Type of Molecule and Phase of Development
Table 10.5  BCMA Targeted Therapies: Distribution by Type of Developer
Table 10.6  BCMA Targeted Therapies: Distribution by Indication
Table 10.7  Funding Instances: Number of Instances, Pre-2007-2017
Table 10.8  Funding Instances: Amount Invested, Pre-2007-2017 (USD Million)
Table 10.9  Funding Instances: Distribution by Type, 2001-2017
Table 10.10  Funding Instances: Distribution by Total Amount Invested, 2001-2017 (USD Million)
Table 10.11  Most Active Players: Distribution by Number of Funding Instances, 2001-2017 (USD Million)
Table 10.12  Most Active Venture Capital Firms / Investors: Distribution by Number of Funding Instances, 2001-2017
Table 10.13  Recent Collaborations: Distribution by Year
Table 10.14  Recent Collaborations: Distribution by Type of Model
Table 10.15  Recent Collaborations: Distribution by Type of Molecule
Table 10.16  Recent Collaborations: Distribution by Type of Molecule and Partnership Model
Table 10.17  Recent Collaborations: Most Active Players
Table 10.18  Overall BCMA Targeted Therapies Market (USD Million), Through 2030, Base Scenario
Table 10.19  Overall BCMA Targeted Therapies Market (USD Million), Through 2030, Optimistic Scenario
Table 10.20  Overall BCMA Targeted Therapies Market (USD Million), Through 2030, Conservative Scenario
Table 10.21  BCMA Targeted Therapies Market: Distribution by Type of Molecule, 2030 (USD Million)
Table 10.22  BCMA Targeted Therapeutics Market: Distribution of Market Share, 2030 (USD Million)
Table 10.23  bb2121 Sales Forecast (USD Million), Through 2030, Base Scenario
Table 10.24  bb2121 Sales Forecast (USD Million), Through 2030, Optimistic Scenario
Table 10.25  bb2121 Sales Forecast (USD Million), Through 2030, Conservative Scenario
Table 10.26  CART-BCMA Sales Forecast (USD Million), Through 2030, Base Scenario
Table 10.27  CART-BCMA Sales Forecast (USD Million), Through 2030, Optimistic Scenario
Table 10.28  CART-BCMA Sales Forecast (USD Million), Through 2030, Conservative Scenario
Table 10.29  Anti-BCMA CAR-T Sales Forecast (USD Million), Through 2030, Base Scenario
Table 10.30  Anti-BCMA CAR-T Sales Forecast (USD Million), Through 2030, Optimistic Scenario
Table 10.31  Anti-BCMA CAR-T Sales Forecast (USD Million), Through 2030, Conservative Scenario
Table 10.32  Anti-BCMA CAR-T Sales Forecast (USD Million), Through 2030, Base Scenario
Table 10.33  Anti-BCMA CAR-T Sales Forecast (USD Million), Through 2030, Optimistic Scenario
Table 10.34  Anti-BCMA CAR-T Sales Forecast (USD Million), Through 2030, Conservative Scenario
Table 10.35  GSK2857916 / J6M0-mcMMAF Sales Forecast (USD Million), Through 2030, Base Scenario
Table 10.36  GSK2857916 / J6M0-mcMMAF Sales Forecast (USD Million), Through 2030, Optimistic Scenario
Table 10.37  GSK2857916 / J6M0-mcMMAF Sales Forecast (USD Million), Through 2030, Conservative Scenario
Table 10.38  AMG 420 / BI 836909 Sales Forecast (USD Million), Through 2030, Base Scenario
Table 10.39  AMG 420 / BI 836909 Sales Forecast (USD Million), Through 2030, Optimistic Scenario
Table 10.40  AMG 420 / BI 836909 Sales Forecast (USD Million), Through 2030, Conservative Scenario
Table 10.41  Overall BCMA Targeted Therapies Market Summary (USD Million): 2024, 2027, 2030

Listed Companies

  1. AbbVie
  2. ABN AMRO
  3. Abramson Cancer Center of the University of Pennsylvania
  4. Acorn Campus Ventures
  5. ADC Therapeutics
  6. Adimab
  7. Aduro Biotech
  8. Advanced Technology Ventures
  9. Aeris Capital
  10. Affimed
  11. Alaska Permanent Fund
  12. Alexo Therapeutics
  13. Alta Partners
  14. Amgen
  15. Aquilo Capital Management
  16. ARCH Venture Partners
  17. Atlante Biotech
  18. Autolus
  19. BankInvest Biomedical Venture
  20. Baylor College of Medicine
  21. Bezos Expeditions
  22. BioMedInvest
  23. bluebird bio
  24. Boehringer Ingelheim
  25. Bristol-Myers Squibb
  26. California Institute for Biomedical Research
  27. California Institute for Regenerative Medicine
  28. Cancer Institute, University College London
  29. Celgene
  30. Cellectis
  31. Commercial Street Capital
  32. Cowen and Company
  33. Credit Suisse Securities
  34. Dana-Farber Cancer Institute
  35. Deerfield Partners
  36. Diamond Capital Company
  37. Discover Growth Fund
  38. Domain Associates
  39. Easton Capital
  40. Edmond de Rothschild Investment Partners
  41. EngMab
  42. Eureka Therapeutics
  43. firstVentury Equity
  44. Five Prime Therapeutics
  45. Forbion Capital Partners
  46. French Muscular Dystrophy Association (AFM)
  47. Genzyme Ventures
  48. GlaxoSmithKline (GSK)
  49. Harbinger Venture Capital
  50. Health Canada
  51. Healthcap Venture Capital
  52. Heidelberg Pharma
  53. Hercules Technology Growth Capital
  54. Idinvest Partners
  55. Immune Pharmaceuticals
  56. Institute of Molecular and Cell Biology
  57. Janssen Pharmaceuticals
  58. Janssen Biotech
  59. Jefferies
  60. Johnson & Johnson
  61. JP Morgan Bay Area Equity Fund
  62. Juno Therapeutics
  63. Kite Pharma
  64. Kleiner Perkins Caufield & Byers
  65. Life Sciences Partners
  66. Majuven
  67. Malin Corporation
  68. Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC)
  69. McMaster University
  70. MedImmune
  71. Memorial Sloan Kettering Cancer Center (MSKCC)
  72. Merlin Nexus
  73. Methodist Hospital, Houston
  74. Micromet
  75. Millennium Pharmaceuticals
  76. National Cancer Institute (NCI)
  77. Novartis
  78. Novartis Institute for Biomedical Research
  79. Novartis-Penn Center for Advanced Cellular Therapeutics
  80. Novo Nordisk
  81. Odyssee Venture
  82. Onyx Pharmaceuticals
  83. OrbiMed
  84. Pfizer
  85. Pontifax
  86. Poseida Therapeutics
  87. RA Capital
  88. Ramius Capital Group
  89. Ridgeback Capital Management
  90. Riverbank Capital
  91. Seattle Genetics
  92. Shire
  93. Singapore BioInnovations
  94. Southwest Hospital of the Third Military Medical University, China
  95. Stifel
  96. Suma Venture
  97. Sutro Biopharma
  98. Takeda Pharmaceutical
  99. Techno Venture Management Capital
  100. Texas Children’s Hospital
  101. Texas Pacific Group
  102. The Scripps Research Institute
  103. The University of Texas MD Anderson Cancer Center
  104. The Wellcome Trust
  105. Third Rock Ventures
  106. Transposagen Biopharmaceuticals
  107. Triumvira Immunologics
  108. University of Munich
  109. venBio
  110. Venrock
  111. Versant Ventures
  112. WILEX
  113. Wuhan Bio-Raid Biotechnology
  114. Yuan Capital

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com